Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,272,116
  • Shares Outstanding, K 111,982
  • Annual Sales, $ 605,220 K
  • Annual Income, $ -168,630 K
  • EBIT $ -177 M
  • EBITDA $ -191 M
  • 60-Month Beta 0.73
  • Price/Sales 1.95
  • Price/Cash Flow N/A
  • Price/Book 3.74

Options Overview Details

View History
  • Implied Volatility 126.96% (+1.01%)
  • Historical Volatility 84.15%
  • IV Percentile 98%
  • IV Rank 80.32%
  • IV High 146.13% on 02/13/26
  • IV Low 48.72% on 06/06/25
  • Expected Move (DTE 27) 2.64 (23.20%)
  • Put/Call Vol Ratio 1.63
  • Today's Volume 2,657
  • Volume Avg (30-Day) 1,415
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 37,469
  • Open Int (30-Day) 24,918
  • Expected Range 8.73 to 14.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.47
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +32.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.82 +15.68%
on 02/09/26
14.97 -24.11%
on 02/12/26
-1.66 (-12.72%)
since 01/20/26
3-Month
9.82 +15.68%
on 02/09/26
15.15 -25.02%
on 01/09/26
-0.10 (-0.87%)
since 11/20/25
52-Week
9.82 +15.68%
on 02/09/26
22.30 -49.06%
on 02/26/25
-10.29 (-47.53%)
since 02/20/25

Most Recent Stories

More News
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3...

NVCR : 11.36 (-0.26%)
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44 th Annual...

NVCR : 11.36 (-0.26%)
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank...

NVCR : 11.36 (-0.26%)
Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley...

NVCR : 11.36 (-0.26%)
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the 37 th Annual Piper Sandler Healthcare Conference in New York on Tuesday, December 2, 2025. William Doyle,...

NVCR : 11.36 (-0.26%)
Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer,...

NVCR : 11.36 (-0.26%)
NovoCure: Q3 Earnings Snapshot

NovoCure: Q3 Earnings Snapshot

NVCR : 11.36 (-0.26%)
Novocure Reports Third Quarter 2025 Financial Results

Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor...

NVCR : 11.36 (-0.26%)
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague,...

NVCR : 11.36 (-0.26%)
Wedbush Remains a Hold on NovoCure (NVCR)

Wedbush analyst David Nierengarten maintained a Hold rating on NovoCure today and set a price target of $18.00. The company’s shares closed last Friday at $13.49.Elevate Your Investing Strategy: Take...

NVCR : 11.36 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

3rd Resistance Point 11.88
2nd Resistance Point 11.67
1st Resistance Point 11.52
Last Price 11.36
1st Support Level 11.16
2nd Support Level 10.95
3rd Support Level 10.80

See More

52-Week High 22.30
Fibonacci 61.8% 17.53
Fibonacci 50% 16.06
Fibonacci 38.2% 14.59
Last Price 11.36
52-Week Low 9.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar